Women's Imaging

The economic environment for breast imaging is already complex and still evolving. Keeping up requires understanding the dynamics at work.

Seven years after the FDA approved the first tomosynthesis device for breast cancer screening, adoption rates for digital breast tomosynthesis (DBT) remain on an upswing. Earlier this year the agency reported a nearly 30 percent increase of certified mammography facilities offering DBT—aka “3D mammography,” aka “tomo”—over just the past year (from 3,178 facilities in March 2017 to 4,074 in March 2018).